Abstract / Description of output

INTRODUCTION: Genetic variation in the apolipoprotein E (APOE) gene is associated with Alzheimer’s disease (AD) and risk factors for cardiovascular disease (CVD). DNA methylation at APOE has been associated to altered cognition and AD. It is unclear if epigenetic marks could be used for predicting future disease.

METHODS: We assessed blood-based DNA methylation at 13 CpGs in the APOE gene in 5828 participants from the Generation Scotland (GS) cohort. Using linear regression, we examined the relationship between APOE methylation, cognition, cholesterol, and the risks for AD and CVD.

RESULTS: DNA methylation at two CpGs was associated with the ratio/quotient of total cholesterol and HDL cholesterol, but not with cognition, or the risks of AD or CVD.

DISCUSSION: APOE methylation could be involved in the levels of blood cholesterol, but there is no evidence for the utility of APOE methylation as a biomarker for predicting AD or CVD.
Original languageEnglish
JournalAlzheimer's and Dementia: Translational Research and Clinical Interventions
Issue number1
Early online date27 Apr 2020
Publication statusE-pub ahead of print - 27 Apr 2020

Keywords / Materials (for Non-textual outputs)

  • APOE
  • DNA methylation
  • Alzheimer’s disease
  • cardiovascular disease
  • cholesterol
  • biomarker


Dive into the research topics of 'DNA methylation in APOE: The relationship with Alzheimer’s and with cardiovascular health'. Together they form a unique fingerprint.

Cite this